Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    bioAffinity Technologies ...

    NASDAQ: BIAF · Real-Time Price · USD
    0.29
    0.01 (2.04%)
    At close: Jun 09, 2025, 3:59 PM
    2.04%
    Bid 0.26
    Market Cap 8.16M
    Revenue (ttm) 8.81M
    Net Income (ttm) -9.74M
    EPS (ttm) -0.71
    PE Ratio (ttm) -0.4
    Forward PE -1.58
    Analyst Buy
    Ask 0.3
    Volume 696,876
    Avg. Volume (20D) 12,390,061
    Open 0.29
    Previous Close 0.28
    Day's Range 0.28 - 0.29
    52-Week Range 0.16 - 2.99
    Beta 2.56

    About BIAF

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol BIAF
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for BIAF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 weeks ago
    +46.84%
    BioAffinity Technologies shares are trading higher... Unlock content with Pro Subscription
    1 month ago
    -44.5%
    BioAffinity Technologies shares are trading lower after the company announced the pricing of its $3.25 million offering.
    news image

    3 weeks ago · businesswire.com

    bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

    SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces new patent for method of selectively killing cancer by targeting two specific receptors on the cell membrane.

    news image

    1 month ago · zacks.com

    BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline

    bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.

    news image

    1 month ago · businesswire.com

    bioAffinity Technologies Reports First Quarter 2025 Results

    SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports first-quarter 2025 results.

    news image

    1 month ago · businesswire.com

    bioAffinity Technologies Announces Closing of $3.25 Million Offering

    SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million.

    news image

    1 month ago · businesswire.com

    bioAffinity Technologies Announces Pricing of $3.25 Million Offering

    SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the pricing of a best efforts offering of securities for aggregate gross proceeds of $3.25 million.

    news image

    2 months ago · businesswire.com

    bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

    SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs.

    news image

    2 months ago · zacks.com

    BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues

    bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.

    news image

    2 months ago · businesswire.com

    bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

    SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (BIAF) releases financial results for 2024.

    news image

    2 months ago · businesswire.com

    Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

    SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.

    news image

    3 months ago · businesswire.com

    Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

    SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.

    Add to Watchlist